- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05835973
Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients. (RECIDREAM)
Evaluation of Sleep Changes as Early Markers of Relapse in Patients With Inflammatory Bowel Diseases (IBD).
Inflammatory Bowel Diseases (IBD) go through two phases: flare and remission. Prediction of flares and identification of patients in remission but at high risk of flare are a major issue when taking care of IBD patients.
Considering close interactions between sleep, immunity and intestinal inflammation, sleep disorders could be a predictor of flares.
The purpose of this study is to demonstrate that sleep efficacy decreases before IBD flare.
Patients in remission will be assessed for IBD symptoms (activity scores, biological factors) and sleep disorders (actigraphy, DREEM®, questionnaires) during one year.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gilles Boschetti, MD,PhD
- Phone Number: +33 4 78 86 13 02
- Email: gilles.boschetti@chu-lyon.fr
Study Contact Backup
- Name: Maelys Cheviakoff
- Phone Number: +33 4 78 86 37 66
- Email: maelys.cheviakoff01@chu-lyon.fr
Study Locations
-
-
-
Clermont-Ferrand, France, 63100
- CHU Clermont-Ferrand, Hôpital d'Estaing
-
Contact:
- Anthony BUISSON
-
Grenoble, France, 38700
- CHU Grenoble Hôpital Michallon-Site Nord
-
Contact:
- Nicolas MATHIEU
-
Pierre-Bénite, France, 69310
- Lyon Sud Hospital
-
Contact:
- Gilles BOSCHETTi, MD,PhD
-
Saint Etienne, France, 42270
- Chu Saint Etienne
-
Contact:
- Xavier Roblin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient over 18 and under 65 years of age.
- Patient with Inflammatory Bowel Disease diagnosed for at least 3 months.
Patient in remission, for at least 3 months:
- clinical remission: Harvey-Bradshaw score (HBI) < 5 for CD and a Mayo score < 3 for UC
- and biological remission: absence of objective inflammation defined by CRP < 5 mg/L and/or fecal calprotectin < 250 µg/g.
- Patient must sign informed consent form to participate to the study.
- Patient affiliated to or benefiting from a social security plan.
Exclusion Criteria:
- Patient with complications (obstructive symptoms, fistulas or intra-abdominal abscesses in the previous three months).
- Patient with extensive bowel resection (> 40 cm of small bowel).
- Patient with an ileostomy or colostomy.
- Patient diagnosed with sleep disorders.
- Patient without legal capacity to consent.
- Pregnant, parturient or nursing women.
- Persons deprived of liberty by judicial or administrative decision.
- Persons under psychiatric care.
- Persons admitted to a health or social institution for purposes other than research.
- Persons of full age who are subject to a legal protection measure (guardianship, curators).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sleep activity
Actigraphy : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard). They will be provided by the company camntech. Ancillary Study: DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months. |
Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard). Ancillary study : DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months. The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management. The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of relapse
Time Frame: 12 months after baseline
|
For Crohn's disease: Harvey Bradshaw Index ≥ 5 AND a CRP > 5 mg/L and/or calprotectin > 250 µg/g For ulcerative colitis: Mayo ≥ 3 AND a CRP > 5 mg/L and/or calprotectin > 250 µg/g Sleep efficiency will be measured by actimetry and expressed as a percentage. Sleep efficiency is defined as the ratio of total time spent asleep compared to total time spent in bed. An actinometer will collect one efficiency measurement per night; an average per week will then be calculated from the daily measurements. |
12 months after baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep efficiency calculated by actimetry and expressed in percentage.
Time Frame: 12 months after baseline
|
Patient will wear actimeters on the wrist for 1 year continuously.
|
12 months after baseline
|
Intra-sleep wakefulness duration (min), sleep latency (min) and sleep duration (min)
Time Frame: 12 months after baseline
|
Intra-sleep wakefulness duration (min), sleep latency (min) and sleep duration (min) will be measured with an actinometer, and averaged per week.
Patient will wear actinometers on the wrist for 1 year continuously.
|
12 months after baseline
|
total sleep time
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
sleep onset latency
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
intra-sleep wake duration
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
polysomnographic sleep efficiency
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
quantity of different sleep stages
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
index of micro-arousals
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
spindle density
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
delta spectral power in slow wave sleep
Time Frame: 12 months after baseline
|
Sleep parameters evaluated by headband are:
|
12 months after baseline
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL22_0907
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Sleep activity
-
King's College LondonCompleted
-
Uppsala UniversityRecruitingMyasthenia GravisSweden
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
GLSMED Learning Health S.A.Recruiting
-
Suleyman Demirel UniversityCompleted
-
Universitat de LleidaInstitut de Recerca Biomèdica de Lleida; Horizon 2020 - European CommissionRecruitingObstructive Sleep ApneaSpain
-
Halic UniversityCompletedSleep Initiation and Maintenance DisordersTurkey
-
Fatih Sultan Mehmet Training and Research HospitalActive, not recruiting
-
Northwestern UniversityShirley Ryan AbilityLabTerminatedParkinson's Disease | Hypersomnia | Poor Quality SleepUnited States
-
Istanbul Kültür UniversityWithdrawnPhysical Activity Level | Physical Activity Awareness